Primary biliary adenosarcoma of the liver —a special and new entity

AbstractPrimary sarcoma of the liver (PSL) is a rare entity accounting for less than 1% of all liver cancers, with unknown aetiology. Several subtypes have been recognized, with histology playing an essential role in patient tailoring and management. We are about to report a case of an unusual PSL, with peculiar morphologic and immunohistochemical properties. A 65-year-old female with a multicystic hepatic lesion underwent surgery due to spontaneous rupture. Pathology revealed dilated bile duct-like structures lined by benign cuboidal/columnar epithelium surrounded by neoplastic proliferation of spindle and epithelioid cells with interspersed osteoclast-like multinucleated giant cells, loosely arranged in a storiform pattern, positive for CD10. The conjugation of morphology and immunohistochemistry results provided the diagnosis of primary biliary adenosarcoma of the liver, biliary type. The patient experienced tumour relapse and died of disease 2  years and 7 months later.
Source: Virchows Archiv - Category: Pathology Source Type: research

Related Links:

Conditions:   Malignant Rhabdoid Tumor;   Rhabdoid Tumor of the Kidney;   Epithelioid Sarcoma;   Chordoma (Poorly Differentiated or De-differentiated);   Atypical Teratoid/Rhabdoid Tumor;   Other INI1 Negative Malignant Tumors (With PI Approval) Interventions:   Drug: Nivolumab;   Drug: Ipilimumab Sponsor:   Dana-Farber Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Benjamin RS Abstract Osteosarcoma was initially resistant to chemotherapy that worked for Ewing sarcoma and rhabdomyosarcoma as well as other chemotherapeutic agents available in the 1960s. In the early 1970s, responses of osteosarcoma to adriamycin were reported, and at about the same time, so were responses of osteosarcoma to high-dose methotrexate. These agents were introduced into adjuvant therapy due to the dire prognosis associated with apparently localized osteosarcoma. After initial questions regarding the role of chemotherapy delayed its uniform acceptance, there is now general agreement that chem...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Osimertinib was approved by the Food and Drug Administration in 2018 for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients. At first, osimertinib was used only for patients with acquired T790  M mutations after 1st and/or 2nd generation EGFR tyrosine kinase inhibitor (TKI) treatment, but it more recently began to be used in first line treatment of EGFR-mutant patients.[1] Despite good initial responses, patients developed resistance to second-line osimertinib treatment, with a median t ime to progression of 10.1 months.[2] Several mechanisms to explain this r...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Background: Programmed cell death 1 ligand-1 (PD-L1) is an immune checkpoint molecule that acts to protect cancer cells from immune surveillance and is considered as a prognostic biomarker in several cancers, but the prognostic value of PD-L1 in bone and soft tissue sarcomas remains inconclusive. In the present meta-analysis, the clinicopathological and prognostic value of PD-L1 in sarcomas was evaluated.Method: We performed a systemic and comprehensive meta-analysis by searching the PubMed, Medline, Cochrane Library, EMBASE, and Web of Science databases up to October 31, 2019. Eligible articles were incorporated, and pool...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The detection of Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations in colorectal cancer (CRC) is key to the optimal design of individualized therapeutic strategies. The noninvasive prediction of...
Source: BMC Medical Imaging - Category: Radiology Authors: Tags: Research Article Source Type: research
Abstract Purpose: Epithelioid hemangioendothelioma (EHE) is an ultra-rare vascular sarcoma with unique clinical features. EHE is characterized by an unpredictable, often protracted, clinical course and highly variable clinical presentation. Due to difficulty recruiting ultra-rare cancer patients, health-related quality of life (HRQoL) of EHE patients has not yet been studied. The aim of this study was to assess EHE symptom burden and its impact on HRQoL and psychological distress.Methods: The study was initiated after EHE patients' foundations approached our research group to study HRQoL. Patients were recruited f...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Abstract A study was presented in which sarcomas were microinjected simultaneously with several drugs to study the pharmacodynamic response after resection. This platform may represent a future way of probing efficacy of anticancer agents in the relevant model system: human tumors. PMID: 32482905 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
We report a rare case of antisynthase syndrome (ASS) complicated with Kaposi sarcoma, analyze its clinical characteristics, and review the literature on the topic. An 80 ‐year‐old male patient developed fever, cough, and shortness of breath. Lung high‐resolution computed tomography showed nonspecific interstitial pneumonia in both lungs, and myositis antibody examination showed strongly positive anti‐alanyl tRNA synthase (PL‐12) antibodies. Based on these findings, the patient was diagnosed with ASS. After full‐dose glucocorticoid treatment, the symptoms of fever and cough were relieved, but skin thickening and...
Source: International Journal of Rheumatic Diseases - Category: Rheumatology Authors: Tags: APLAR GRAND ROUND CASE Source Type: research
ABSTRACTThe overall prognosis of patients with sarcoma ‐based cancers has changed little in the last 20 years. There is an urgent need to investigate the metastatic potential of these tumors and to develop anti‐metastatic drugs. It is becoming increasingly clear that platelets play an important role in the establishment of metastasis of carcinoma cells and could be a useful therapeutic target for patients with carcinoma. However, little is known about the role of platelets in sarcoma progression. Here, we investigated how osteosarcoma progression relates to platelet function to explore the possibility of anti‐...
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Tags: Original Article Source Type: research
BRAF structures and their activation mechanisms. AbstractThe mitogen ‐activated protein kinase (MAPK) signaling pathway plays a significant role in mediating cellular physiological activities, such as proliferation, differentiation, apoptosis, and senescence. This signaling pathway is composed of several major proto ‐oncogenes ofRAS/RAF/MEK/ERK, among which theBRAF proto ‐oncogene, as one of the three members of theRAF family, has a higher mutation rate thanARAF andCRAF and has attracted extensive attention. Regarding the BRAF mutation, approximately 95% of BRAF mutations belong to the BRAF V600E mutation, which can ...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research
More News: Bile | Cancer | Cancer & Oncology | Liver | Pathology | Sarcomas | Urology & Nephrology